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Abstract
Purpose Increased expression of glial fibrillary acidic protein
(GFAP) is a characteristic of gliotic activation (Müller cells
and astrocytes) in the retina. This study assessed vitreous body
GFAP levels in various forms of retinal pathology.
Methods This prospective study included 82 patients who
underwent vitrectomy (46 retinal detachments (RDs), 13 mac-
ular hole (MHs), 15 epiretinal glioses (EGs), 8 organ donors).
An established enzyme–linked immunosorbent assay
(ELISA, SMI26) was used for quantification of GFAP.
Results The highest concentration of vitreous body GFAP in
organ donors was 20 pg/mL and it was used as the cutoff. A
significant proportion of patients suffering from RD (65 %) to
EG (53 %) had vitreous body GFAP levels above this cutoff
when compared to organ donors (0 %, p<0.0001, p=0.0194,
respectively, Fisher’s exact test) and MH (8 %, p<0.0001, p=
0.0157, respectively). In RD and EG, vitreous body GFAP
levels were correlated with axial length (R=0.69, R=0.52,
p<0.05 for both).
Conclusions The data suggest that human vitreous body
GFAP is a protein biomarker for glial activation in response
to retinal pathologies. Vitreous body GFAP levels may be of
interest as a surrogate outcome for experimental treatment
strategies in translational studies.
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Introduction
Glial fibrillary acid protein (GFAP) is a protein biomarker for
astrocytes and activated Müller cells [1]. Müller cells are the
principle glial cells in the neural retina, being involved in the
homoeostasis and metabolism of retinal neurons [2, 3], and
they penetrate the entire human retina in radial columns. As-
trocytes are only found within the retinal nerve fibre layer
(RNFL) and, notably, the optic nerve head (ONH). This pro-
tein biomarker is a non–soluble, 432-amino acid cytoskeletal
protein belonging to the class–III intermediate filament pro-
teins [1, 4]. Discovered in 1969, it is encoded on chromosome
17q21.1-q25 [1, 5]. Under normal conditions, GFAP is not
expressed in Müller cells.
Activation of Müller cells including increased expres-
sion of GFAP is a key response feature of the human
retina to injury and a sign of age-related subclinical
pathologies [6]. It includes morphological, biochemical,
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and physiological changes in Müller cells and has
mixed effects, contributing to neuroregeneration includ-
ing protease activation, but also to neurodegeneration
with impediment of tissue repair [3]. Müller cells are
responsible for scar formation after retinal detachment
with devastating consequences for recovery of visual
function [6].
The up-regulation of GFAP within the Müller cells is
a remarkably ubiquitous response in retinal pathology
[7] and the most sensitive non-specific response to ret-
inal disease and injury. Of note, GFAP is not required
for normal functioning of Müller cells, only for Müller
cell gliosis. Disintegration of Müller cells triggers cellu-
lar proteolysis. With proteolytic break–up of the GFAP
polymer, soluble fragments of GFAP are released to the
adjacent fluid compartments [1, 8]. This process is cal-
cium dependent and calpain-mediated release of a
41 kDa fragment dominates over other, smaller proteo-
lytic break-down products of GFAP [1].
Therefore, GFAP might be used as an indirect marker
for retinal injury, Müller cell activation, protease activa-
tion and finally secondary degenerative processes in the
retina [2, 7]. Notably, there is experimental and clinical
evidence for increased GFAP expression in retinal Müll-
er cells in RD [9–14] and proliferative vitreoretinopathy
[15, 16]. Furthermore, the intraretinal glial response ap-
pears to be centrally involved in the formation of
epiretinal gliosis (EG) [7]. Vitreous body proteomics
has emerged as a tool to better understand and quantify
the cellular processes underlying ocular disease [17, 18].
An advantage of enzyme-linked immunosorbent assay
(ELISA) techniques is that the advanced analytical sen-
sitivity allows detection of minute amounts of protein in
a high throughput setting [1].
Therefore, we hypothesized that using a sensitive ELISA
for GFAP [19] on vitreous body material from patients with
RD and EGmight permit us to detect GFAP from the human
vitreous body, although GFAP has not yet been reported to
be present in the vitreous body before. Interestingly, it was
even absent in a large-scale proteomic study of patients suf-
fering from a proliferative vitreoretinopathy (PVR), which
revealed 97–137 vitreous body proteins [20]. This is sur-
prising because GFAP is such an abundant protein, extreme-
ly stable and well suited for mass spectrometry [21]. Of
note, the study by Yu et al. detected another intermediate
filament, the neurofilament protein, albeit at a very low lev-
el. Using a highly sensitive ELISA, we previously described
vitreous body neurofilament levels in a range of retinal pa-
thologies [22]. We further hypothesised that, if detectable,
vitreous body GFAP levels would be higher in these condi-
tions compared with normal controls or patients with mac-
ular holes (MHs), where glial retinal pathology is less
dominant.
Materials and methods
Patients
This study was approved by the ethics committees of the local
clinical centres (Lublin, Poland and Erlangen, Germany) and
adhered to the tenets of the Declaration of Helsinki. Acquisi-
tion of research samples was limited to routine sampling pro-
cedures. As a control, we included vitreous body material
from cadaveric ocular tissue.
Vitreous body homogenate
Vitreous body samples were collected from 74 patients who
underwent vitrectomy for RD (n=46), EG (n=15) and MH
surgery (n=13). Because it is ethically not possible to obtain
vitreous body from healthy controls, we also included organ
donors (n=8). All samples were coded, snap–frozen and
stored at −80 °C until analysis. On receipt in London, the
samples were thawed and homogenised on ice using a Sonipre
150 (power 14, one minute). The homogenate was spun down
(4 °C, 150,000 rpm, 10 min) and the supernatant was used for
analysis.
Sample analysis
All samples were analysed with the analyst being blinded to
all other data.
A previously described, an ELISA technique was used to
quantify vitreous body homogenate levels of GFAP [19]. In
brief, microtitre plates were coated overnight with 100 μL
of the SMI26 capture antibody and diluted 1/5000 in 0.05-
M carbonate buffer, pH 9.5. The plate was washed with
barbitone buffer containing 6-mM EDTA, 0.1-% bovine se-
rum albumin BSA and 0.05-% Tween 20 (pH 8.6). The plate
was blocked with 250 μL of barbitone buffer containing
6 mM EDTA and 1 % of BSA. After washing, 50 μL of
barbitone buffer, 6-mM EDTA, 0.1-% BSA were added as
sample diluent to each well. Fifty μL of standard or vitreous
body homogenate samples were then added in duplicate to
the plate. The plate was incubated at room temperature (RT)
for 1 h. After washing, 100 μL of of horseradish peroxidase
(HRP)-labelled rabbit anti-bovine GFAP diluted 1:1000 in
barbitone buffer (6-mM EDTA, 0.1-% BSA) were added to
each well and the plate was incubated for 1 h at RT. After a
final wash, 100 μl of tetramethylbenzidine (TMB) substrate
were added. The plate was incubated for 20 min at RT in the
dark; the reaction was stopped by adding 50 μl 1-M hydro-
chloric acid (HCl) and the absorbance was read at 450 nm
with 750 nm as the reference wavelength on a Wallac Victor
2 ELISA plate reader.
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Data analysis
All statistical analyses and graphs were done using SAS soft-
ware (version 9.4, SAS Institute, Inc., Cary, North Carolina,
USA). Both mean (± standard deviation, SD) and median
values were presented because non–Gaussian distribution in-
dependent variables were compared using the non-parametric
two-sample exact Wilcoxon rank-sum test for two variables
and a two–way unbalanced analysis of variance (ANOVA;
general linear model (GLM)) for more than two variables.
Fisher’s exact test was used for comparing the proportion of
patients with pathological (positive, high) GFAP levels be-
cause of small sample size and distribution. The cut–off above
which results were considered pathological was defined as the
highest value observed in the control group. The linear rela-
tionship between continuous variables was evaluated using
the Spearman correlation coefficient. Multiple correlations
were corrected using the Bonferroni method. Linear regres-
sion analysis was performed using the least squares method.
Results
The demographic features of the patients are summarised in
Table 1. There was no difference in age between the groups
(F=1.40, p=0.3) and there was no correlation between the
patients’ age and the vitreous body GFAP levels for either
the pooled cohort or any of the diagnostic groups.
The highest concentration of GFAP protein found in the
vitreous body from the organ donor control group was
20 pg/mL (horizontal dotted line in Fig. 1). According to this
cut-off, pathological vitreous GFAP levels were found in 8/15
(53 %) of the patients with EG, 1/13 (8 %) patients with MHs
and 30/46 (65 %) patients with RD. The proportion of patients
with pathological vitreous bodyGFAP levels were significant-
ly higher following RD when compared to all organ donors
(two–sided Fisher’s exact test p<0.0001) and MHs
(p<0.0001). Likewise vitreous body GFAP levels were higher
in a significantly larger proportion of patients with EG when
compared to organ donors (two–sided Fisher’s exact test p=
0.0194) and MHs (p=0.0157). There was no significant dif-
ference in vitreous body GFAP levels between patients with
RD and EG (p>0.05).
Figure 1 shows the averaged GFAP levels (+SD) grouped
according to the patients’ diagnosis. The median value of the
organ donors (10 pg/mL, range 10–20 pg/mL) was compara-
ble to the median value following MH surgery (median 10,
range 0 to 30 pg/mL).Medians were higher in EG (median 30,
range 0 to 1100 pg/mL) and RD (70, range 0 to 1100 pg/mL).
Vitreous body GFAP levels were not correlated to the time
delay between onset of symptoms and sampling of the vitre-
ous body (R=−0.09, p=0.6, data not shown).
Patients with myopia (> −0.5 dpt) had significant higher
median vitreous body GFAP levels (50 ng/mL) compared to
those with hyperopia (20 pg/mL, p=0.024, Fig. 2). Addition-
ally, the axial length was correlated with vitreous body GFAP
levels in the pooled cohort (R=0.59, p=0.0005) as well as in
patients with EG (R=0.69, p=0.027) or RD (R=0.52, p=
0.039).
Discussion
In the present study, we found increased levels of GFAP in the
vitreous body of patients with RD and EG. The normal range
of vitreous body GFAP levels was determined from donor
eyes. The normal GFAP levels were below 20 pg/mL. In
RD, the GFAP levels in the vitreous were increased 20-fold,
and in RG, the increase was 10-fold.
To the best of our knowledge, this is the first study quanti-
fying GFAP levels in the human vitreous. GFAP has not yet
been reported to be present in the vitreous body using a differ-
ent technique [21]. Using a highly sensitive ELISA, we previ-
ously described vitreous body neurofilament levels in a range
of retinal pathologies [22]. Thus, highly sensitive ELISA seems
to be necessary to detect GFAP in the vitreous, too [1, 19].
The degenerative vitreous processes potentially induce pa-
thology at the vitreoretinal interface [23, 24]. In RD, Müller
cell hypertrophy and hyperplasia expand into the subretinal
space and vitreous, and is associated with GFAP production
[9, 25–27].
These unspecific responses of Müller cells start within
1 day of detachment [12, 28, 29]. At 3 days of detachment,
the low basal level of GFAP mRNA in the normal retina is
increased to approximately 500 % [26] with GFAP labelling
of Müller cells extending throughout the retina [30]. Elevated
GFAP expression was found in Müller cells in early and long-
term RD. Increased GFAP-containing intermediate filaments
within Müller cells were found in 30- and 60-day detached
retinas, as determined by protein gels, immunoblotting analy-
sis, and light- and electron-microscopic immunocytochemis-
try [9, 31]. Furthermore, tissue autoradiographic studies indi-
cate an increase in RNA synthesis between 2 and 3 days after
RD inMüller cells [32, 33] in parallel with a five-fold increase
in GFAP mRNA at that time using RNA blotting analysis and
in situ hybridization [26].
In the vitreous, further translational studies are needed to
address the time course, GFAP levels and outcome after sur-
gical repair, as upregulation of intermediate filaments seems to
be a crucial step for the gliotic response [3]. Epiretinal,
intraretinal and subretinal reactive gliosis of Müller cells is a
clinically significant limiting factor in the recovery of vision
after reattachment [14, 34, 35]. It has been proposed that at-
tempts to reduce Müller cell gliosis may inhibit subsequent
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retinal degeneration and support neuroregeneration after reat-
tachment [14, 35].
Interestingly, myopic eyes showed significant higher me-
dian GFAP levels in comparison to hyperopic eyes. Even
though the numbers in this study are small, this finding is
consistent with the literature on myopia as a relevant eye con-
dition. Myopic eyes show more and severe retinal degenera-
tion, more frequently RD [36] and, generally, the outcome
from retinal repair surgery remains poorer [37].
The increased GFAP levels in EG in this study indicate the
role ofMüller cells in this retinal disease, too [38]. The normal
levels of GFAP inMHs might be due to different unspecific or
specific responses of Müller cells to the kind of stimulus in
MH disease or to a small lesion size.
The limitations to this study are related to the fact that
GFAP as a soluble protein biomarker can only provide indirect
evidence for retinal pathology. Next, the definition of the cut-
off value was based on organ donors, which cannot be
regarded as a healthy control group. In addition, the post-
mortem interval was not recorded. It is, however, conceivable
that artefactual vitreous GFAP levels in this study are unlikely
because, technically, the removal of the eye is quicker than the
spinal cord where absence of a post-mortem artefact for GFAP
has been demonstrated [39]. In addition, the GFAP levels from
Table 1 Patients characteristics
(mean values±standard
deviation)
Characteristic OD EG MH RD
Number 8 15 13 46
Age 63±18 70±7 70±6 64±15
Gender (F:M) 4:4 8:7 8:5 14:32
Onset to surgery (days) – 503±567 116±55.4 97.1±261
VA – 0.28±0.18 0.18±0.09 0.25±0.27
IOP – 12.3±2.9 13.0±3.2 11.7±4.4
Axial length [mm] – 23.7±1.9 22.8±0.8 24.5±2.3
PVR – – – 8/22 (36 %)
MD – – – 15/22 (68 %)
DM 1/8 (13 %) 1/7 (14 %) 1/4 (25 %) 5/21 (24 %)
RR 1/8 (13 %) 4/7 (57 %) 3/5 (60 %) 10/22 (45 %)
GFAP [pg/mL] 11±4 158±302 12±9 241±342
For those variables where the data was incomplete, the total number of patients (%) is shown.
DM diabetes mellitus, IOP intraocular pressure (mmHg), MD macular detachment, MH macular hole, PVR
proliferative vitreoretinopathy, RD retinal detachment, RR arterial hypertension, EG epiretinal gliosis,MD mac-
ular degeneration, OD organ donors, VA visual acuity. * = results are significantly different compared to patients
with RD
Fig. 1 A protein biomarker for
glial (Müller cell and astrocytes)
damage in retinal disease,
vitreous body GFAP. According
to the upper reference range
(cutoff) of 20 pg/mL (horizontal
reference line) high vitreous body
homogenate GFAP levels were
observed in 0/8 (0 %) of organ
donors (OD), 1/13 (8 %) of pa-
tients with a MH surgery, 8/15
(53 %) of patients with EG and
30/46 (65 %) of patients with
retinal detachment (RD). The
mean and standard deviation are
shown
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patients with a MH were in a comparable range to those from
the organ donors. Taken together, this argues against a bias
introduced by the post-mortem interval of the organ donors in
the present study.
This study did not show a correlation between vitreous
body GFAP levels and time delay onset of symptoms and
sampling. This is likely due to the large time range
(Table 1). This range exceeds what is known about the
detachment-induced proliferation of Müller cells which peaks
within 3 to 4 days [13, 28]. The time lag of an average 91 days
between RD to surgery might explain the lack of a time-GFAP
correlation. But it might be also due to the relative weak power
of historical data regarding the onset of symptoms and the
range of RD duration. Other limitations of this study are the
small numbers and the lack of follow-up. It would be of inter-
est to discern if GFAP levels at time of surgery are of prog-
nostic value in RD and EG. Extending on this limitation, the
heterogeneous delay between symptom onset and sampling
prevented us from performing a systematic investigation of
RD severity with vitreous GFAP levels. Future studies on
the prognostic value of vitreous body GFAP levels should
include such severity data so as to enable testing the hypoth-
esis that higher GFAP levels are present with more severe
disease. Such studies will be a prerequisite for testing the
clinical relevance of this biomarker. Finally, patient numbers
were not equally balanced. There were relatively few patients
with a MH. Therefore, this study cannot exclude a limited
degree of glial activation inMHs as suggested by the literature
[40, 41].
In conclusion, we found, for the first time, increased GFAP
levels in the vitreous of patients suffering from RD and EG.
Because upregulation of GFAP is the most sensitive non-
specific response of Müller cells in retinal disease, vitreous
GFAP levels might act as a biomarker for retinal glial activa-
tion. GFAP levels in the vitreous were also elevated in cases of
myopia. The data suggest that human vitreous body GFAP
may be an interesting protein biomarker for indirect quantifi-
cation of the glial response to retinal disorders. The small
sample volume required for the ELISA can be further reduced
using electrochemiluminescence- or fluorescence-based
methods [1]. This opens avenues for future translational stud-
ies on the cell culture and animal models using vitreous body
GFAP levels as a surrogate outcome.
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